You just read:

Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung

News provided by

Boehringer Ingelheim Pharmaceuticals

Feb 09, 2017, 08:30 ET